Daily FNArena News

Sales growth for the Brambles’ CHEP business reflected strong price realisation and customer expansion in the US, but the critical issue for brokers is easing cost inflation.

Cochlear has launched its MRI-compatible implant but brokers do not expect the new product will impact revenue and market share until FY20.

Elevated inventory persisted over the March quarter amid falling sales for Blackmores, which has recognised the need to reposition its business to better cater for the Chinese market.

Peter Switzer of the Switzer Super Report notes an attack on franking credit refunds could come down to the balance of power in the Senate.

The first quarter can be soft for seasonal reasons and mineral sands producer Iluka Resources has assured the market that sales remain in line with historical averages.

Stuart Roberts of Pitt Street Research talks to Steve Lydeamore, CEO of Anatara Lifesciences.

A change of heart from the US SEC may open the door for rapid growth of actively managed ETFs both in the US and Australia.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. After a long period with a negative or neutral position on Mayne Pharma, Wilsons has decided now is the time to buy.

Michael Gable of Fairmont Equities notes Kogan.com’s recovery appears set for a new phase.

Despite a soft top line in the March quarter, brokers are reasonably confident that jeweller Michael Hill has enough in the kitty to meet FY19 expectations.